HANOI, VIETNAM / ACCESS Newswire / April 14, 2025 / Together with world-renowned scientists including Prof. Joel F. Habener, ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, ...